Amarantus Exercises Exclusive Option with Leipzig University for Alzheimer's Blood Diagnostic "LymPro Test 2.0"
30 mai 2018 08h00 HE
|
Amarantus Bioscience Holdings, Inc.
Scope of exercised Exclusive Option Agreement expanded to include negotiations for IP rights to additional key markers collected in German clinical study, including CSF-tau NEW YORK, May 30, 2018 ...